India markets closed

  • BSE SENSEX

    48,878.54
    -746.22 (-1.50%)
     

  • Nifty 50

    14,371.90
    -218.45 (-1.50%)
     

  • USD/INR

    72.9800
    +0.0300 (+0.04%)
     

  • Dow

    31,005.88
    -170.13 (-0.55%)
     

  • Nasdaq

    13,509.90
    -21.02 (-0.16%)
     

  • BTC-INR

    2,376,137.50
    +152,191.50 (+6.84%)
     

  • CMC Crypto 200

    646.08
    +36.09 (+5.92%)
     

  • Hang Seng

    29,447.85
    -479.91 (-1.60%)
     

  • Nikkei

    28,631.45
    -125.41 (-0.44%)
     

  • EUR/INR

    88.8742
    +0.0795 (+0.09%)
     

  • GBP/INR

    99.7868
    -0.3787 (-0.38%)
     

  • AED/INR

    19.8240
    +0.0080 (+0.04%)
     

  • INR/JPY

    1.4190
    +0.0029 (+0.20%)
     

  • SGD/INR

    54.9940
    -0.1720 (-0.31%)
     
BUDGET 2021:

Will the FM cut taxes to boost the economy?

Budget made easy! Don’t miss our simplified coverage of the Budget 2021-22

Smith looking pretty scary for opposition teams: Maxwell

·2-min read

Sydney, Nov 29 (PTI) In red-hot form, Steve Smith is looking 'pretty scary' for the opposition teams, gushed Australia all-rounder Glenn Maxwell after his teammate hammered his second successive century against India on Sunday.

Smith's quick-fire 104-run knock propelled Australia to a mammoth 389 for four in the second ODI, which they defended easily to secure a decisive 2-0 lead in the ODI series.

'As he said the other day, he has found his hands, he is looking pretty scary at the moment for opposition teams. He is placing the ball as well as anyone around the world. When he puts the foot down, he goes and goes hard,' Maxwell said at the virtual post-match press conference, facilitated by official broadcasters Sony Networks.

'He is picking his spots. He is calculated (on the off-side) and he has got so much time at the moment. A lot of time, you judge him by the way he starts his innings and he just started by hitting the middle of the bat consistently.' Maxwell, who himself contributed in Australia's huge total with his unbeaten 63, said it was great to get a bit of momentum in ODI cricket after struggling in T20s but also credited performing top-order for his success.

'I suppose it comes down to situations and conditions. And Sydney has been a place where I have had a bit of success in the past, a great wicket to bat on, there is always a lot of space out there and I'm trying to find that short boundary.

'But yes, it is been nice to sort of get bit of momentum in ODI cricket. Sometimes it is not easy to find consistency in the long road, but when the top-order is doing their job as well as they are at the moment, that makes my role a lot easier down (at the) bottom,' he said.

Maxwell also said the opening partnership between David Warner and Aaron Finch has been no less than sensational. In both matches their solid start provided the platform for massive totals.

Asked was it a perfect template to build a 50-overs innings, he said,'Yes it certainly has, when you have got a guy like Steve Smith coming in and getting 100 of 62 balls, it's pretty special to watch and it feels like we are just setting the platform beautifully, weathering that early storm and that opening partnership has just been sensational for us.' PTI NRB AT AT

Latest stories

  • We would have to play two different squads against Pakistan, says Graeme Smith

    Cape Town [South Africa], January 22 (ANI): Cricket South Africa (CSA) director of cricket Graeme Smith on Friday revealed that Proteas will use two different teams in the Pakistan tour so that their Test squad members can return home early to begin their quarantine period ahead of the home series against Australia.

  • Data shows slight fall in people testing positive for Covid in England

    Data shows slight fall in people testing positive for Covid in England. Findings chime with the latest R number of between 0.8 and 1.0 for both England and the UK as a whole

  • Hatton takes five-shot lead in Abu Dhabi as fading light stops play

    Hatton, who was one shot behind overnight leader Rory McIlroy, carded an eagle on the par five second and had four birdies in a row from the seventh after a bogey on the third. The 29-year-old Hatton recorded two eagles in the first round and became the first player since McIlroy to card three at the event since the Irishman achieved the feat in 2011. Four other players were tied for second, including McIlroy and Frenchman Romain Langasque -- who are both yet to finish their rounds -- as well as early clubhouse leaders Jazz Janewattananond of Thailand and Australian Jason Scrivener.

  • GoAir offers 1 mn seats at low fares starting Rs 859 on domestic travel

    <p>Mumbai, Jan 22 (PTI) Budget carrier GoAir on Friday put one million seats up for sale on its domestic network at fares starting as low as Rs 859, under a limited-period special offer ahead of the Republic Day.</p>

  • Zidane pressure at Real Madrid, AC Milan title test, Bundesliga top-four fight and what to watch around Europe

    Real Madrid must find a response after being knocked out of the cup by third-tier opposition, or Zinedine Zidane’s job may be in jeopardy

  • ‘There will be a trial’: Trump impeachment articles to be delivered to Senate on Monday, says Schumer

    Hearing could start as soon as next week

  • Avery Design Announces CXL™ 2.0 VIP

    Avery Design Systems, leader in functional verification solutions today announced availability of CXL 2.0 VIP. Computer Express Link™ (CXL) is an open industry-standard interconnect offering coherency and memory semantics using high- bandwidth, low-latency connectivity between host processor and devices such as accelerators, memory buffers, and smart I/O devices

  • Kerala reports 6,753 new cases of COVID-19

    Thiruvananthapuram (Kerala) [India], January 22 (ANI): Kerala reported 6,753 COVID-19 cases on Friday and a person who returned from the UK has been confirmed to have a mutant virus strain.

  • As Covid cases spike, Dubai works to keep its economy open

    As Covid cases spike, Dubai works to keep its economy open. For an emirate dependent on trade, transport and tourism, vaccination, not lockdown, is key to keeping its economy going

  • India, China maintaining close communication on next round of military talks: MEA

    <p>New Delhi, Jan 22 (PTI) India and China have agreed to hold the next round of senior commander-level meeting soon and both sides are maintaining close communication over diplomatic and military channels on it, the Ministry of External Affairs said on Friday.</p>

  • Israeli Covid chief's remarks on vaccine inaccurate, say officials

    Israeli Covid chief's remarks on vaccine inaccurate, say officials. Nachman Ash had said single Pfizer/BioNTech dose was less effective than expected

  • "A Provincial Government That Doesn't Care Much About Children, Workers, or the Truth" – CUPE Responds to Star Report of Ford Government’s Penny-Pinching Strategies for Schools and COVID-19

    CUPE leaders expressed shock but not surprise at the findings in the Toronto Star's investigation into the "watered down" strategies that the Ontario government used to keep COVID-19 out of schools. Laura Walton, president of CUPE’s Ontario School Board Council of Unions (OSBCU), gave the following comment:

  • Quarter of known bee species have not been recorded since 1990

    Quarter of known bee species have not been recorded since 1990Global study finds that species numbers reported in the wild fell sharply between 1990 and 2015

  • Chino Commercial Bancorp Reports 3% Increase in Net Earnings

    CHINO, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Board of Directors of Chino Commercial Bancorp (OTC: CCBC), the parent company of Chino Commercial Bank, N.A., announced the results of operations for the Bank and the consolidated holding company for the fourth quarter ended December 31, 2020. Net earnings for the fourth quarter 2020, were $699 thousand, or an increase of 39.1%, as compared with earnings of $502 thousand for the same quarter last year. The increase in earnings is primarily attributed to the increase in loan interest and loan fee income. Net earnings per basic and diluted share was $0.31 for the fourth quarter of 2020, and $0.23 for the same quarter last year. Dann H. Bowman, President and Chief Executive Officer, stated: “Despite the difficulty being experienced in our community because of COVID, the Bank has performed well during this time. By assisting small business customers and households, we have experienced a 37% increase in total assets, a 35% increase in total loans, and a 2.7% increase in net after tax earnings. Loan quality also remains very strong, with the Bank having no loan delinquencies and no foreclosed properties at year-end. “We believe that during tough times like these, the Bank’s value proposition stands out the most, and we may have many more opportunities to gain new banking relationships. We have a great team, a great market, and we are excited about the prospects for the Company over the next several years.” Financial Condition At December 31, 2020, total assets were $314.8 million, an increase of $85.3 million or 37.2% over $229.5 million at December 31, 2019. Total deposits increased by 43.1% or $77.6 million to $257.7 million as of December 31, 2020, compared to $180.2 million as of December 31, 2019. At December 31, 2020, the Company’s core deposits represent 96.3% of the total deposits. Gross loans increased by 35.5% or $51.3 million as of December 31, 2020 to $195.7 million, as compared with $144.4 million as of December 31, 2019. The Bank had one non-performing loan for the quarters ended December 31, 2020, and December 31, 2019. OREO properties remained at zero as of December 31, 2020 and December 31, 2019 respectively. The increases in total assets, deposits and loans are attributed to Bank’s response to the overwhelming request of PPP loans. Overall, the Bank approved and funded 396 PPP loans with an outstanding balance of $46.7 million as of December 31, 2020. Earnings The Company posted net interest income of $2.3 million for the three months ended December 31, 2020 and $2.0 million for the same quarter last year. Average interest-earning assets were $292.2 million with average interest-bearing liabilities of $136.3 million, yielding a net interest margin of 3.66% for the fourth quarter of 2020, as compared to the average interest-earning assets of $177.3 million with average interest-bearing liabilities of $119.4 million, yielding a net interest margin of 4.41% for the fourth quarter of 2019. Non-interest income totaled $440.2 thousand for the fourth quarter of 2020, or a decrease of 3.6% as compared with $456.6 thousand earned during the same quarter last year. The majority of the decrease is attribute to a significant decrease in overdraft fees. General and administrative expenses were $1.8 million for the three months ended December 31, 2020, and $1.7 million for the same period last year. The largest component of general and administrative expenses was salary and benefits expense of $1.1 million for the fourth quarter of 2020 and $1.0 million thousand for the same period last year. Income tax expense was $275.3 thousand which represents an increase of $78 thousand or 39.8% for the three months ended December 31, 2020, as compared to $197.0 thousand for the three months ended December 31, 2019. The effective income tax rate for the fourth quarter of 2020 and 2019 were approximately 28.6% and 28.5% respectively, and for the nine months ending December 31, 2020 and 2019, the effective income tax rates were 28.3% and 28.2% respectively. Forward-Looking Statements The statements contained in this press release that are not historical facts are forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects on the Company. Readers are cautioned not to unduly rely on forward-looking statements. Actual results may differ from those projected. These forward-looking statements involve risks and uncertainties, including but not limited to, the health of the national and California economies, the Company’s ability to attract and retain skilled employees, customers’ service expectations, the Company’s ability to successfully deploy new technology and gain efficiencies therefrom, and changes in interest rates, loan portfolio performance, and other factors. Contact: Dann H. Bowman, President and CEO or Melinda M. Milincu, Vice President and CFO, Chino Commercial Bancorp and Chino Commercial Bank, N.A., 14245 Pipeline Avenue, Chino, CA. 91710, (909) 393-8880. CHINO COMMERCIAL BANCORPCONSOLIDATED BALANCE SHEETDecember 31, 2020 and December 31, 2019 December 31, 2020 December 31, 2019 (unaudited) (audited)ASSETS: Cash and due from banks$58,075,217 $4,363,753 Federal funds sold - 32,415,000 Total cash and cash equivalents 58,075,217 36,778,753 Interest-bearing deposits in other banks - 496,000 Investment securities available for sale 32,370,042 7,977,936 Investment securities held to maturity (fair value approximates $19,556,250 at December 31, 2020 and $21,683,834 at December 31, 2019) 18,626,525 28,367,056 Total investments 50,996,567 36,840,992 Loans Construction 1,014,462.00 - Real estate 119,302,116 115,633,626 Commercial 75,237,752 28,522,543 Installment 110,475 232,328 Credit Cards 0 - Gross loans 195,664,805 144,388,497 Unearned fees and discounts (1,678,641) (438,380)Loans net of unearned fees and discount 193,986,164 143,950,117 Allowance for loan losses (3,271,921) (2,391,765)Net loans 190,714,243 141,558,352 Fixed assets, net 6,145,711 6,401,773 Accrued interest receivable 1,013,732 619,856 Stock investments, restricted, at cost 1,554,200 1,440,900 Bank-owned life insurance 4,721,232 4,595,584 Other assets 1,618,716 1,270,936 Total assets$314,839,618 $229,507,145 LIABILITIES: Deposits Non-interest bearing$145,433,815 $88,412,668 Interest bearing NOW and money market 76,774,420 64,520,387 Savings 21,466,856 12,209,281 Time deposits less than $250,000 9,563,300 9,537,555 Time deposits of $250,000 or greater 4,473,409 5,471,451 Total deposits 257,711,800 180,151,342 Accrued interest payable 137,487 203,246 Borrowings from Federal Home Loan Bank (FHLB) 25,000,000 20,000,000 Accrued expenses & other payables 1,674,150 1,686,979 Subordinated notes payable to subsidiary trust 3,093,000 3,093,000 Total liabilities 287,616,437 205,134,567 SHAREHOLDERS' EQUITY Common stock, authorized 10,000,000 shares with no par value, issued andoutstanding 2,230,808 shares at December 31, 2020 and December 31, 2019,respectively. 10,502,558 10,502,557 Retained earnings 16,428,258 13,803,528 Accumulated other comprehensive income/(loss) 292,365 66,493 Total shareholders' equity 27,223,181 24,372,578 Total liabilities & shareholders' equity$314,839,618 $229,507,145 CHINO COMMERCIAL BANCORPCONSOLIDATED STATEMENTS OF NET INCOME For the three months ended For the twelve months ended December 31 December 31 2020 2019 2020 2019 (unaudited) (unaudited) (unaudited) (unaudited)Interest income Interest and fee income on loans$2,624,645 $1,982,610 $9,207,404 $7,884,573Interest on federal funds sold and FRB deposits 14,194 184,875 154,934 510,650Interest on time deposits in banks - 3,219 1,856 35,077Interest on investment securities 225,264 167,707 912,489 1,078,908Total interest income 2,864,103 2,338,411 10,276,683 9,509,208 Interest Expense Interest on deposits 53,723 230,243 369,628 935,215Other borrowings 124,947 139,476 511,815 413,749Total interest expense 178,670 369,719 881,443 1,348,964Net interest income 2,685,433 1,968,692 9,395,240 8,160,244Provision for loan losses 400,000 - 770,000 40,000 Net interest income after provision for loan losses 2,285,433 1,968,692 8,625,240 8,120,244 Non-interest income Service charges on deposit accounts 342,342 382,839 1,293,966 1,530,853Other miscellaneous income 47,642 24,567 163,513 190,565Dividend income from restricted stock 18,421 17,267 71,664 88,281Income from bank-owned life insurance 31,840 31,901 125,648 110,699Total non-interest income 440,245 456,574 1,654,791 1,920,398 Non-interest expenses Salaries and employee benefits 1,064,780 1,002,259 4,058,653 3,941,211Occupancy and equipment 160,415 155,473 623,102 632,501Data and item processing 147,958 123,409 589,351 469,176Advertising and marketing 33,869 30,867 144,167 97,035Legal and professional fees 76,075 217,088 209,565 430,050Regulatory assessments 33,480 (12,940) 116,167 81,578Insurance 10,567 10,295 38,380 37,911Directors' fees and expenses 32,040 32,742 130,054 137,142Other expenses 192,528 166,709 692,057 675,289Total non-interest expenses 1,751,712 1,725,902 6,601,496 6,501,893Income before income tax expense 973,966 699,364 3,678,535 3,538,749Income tax expense 275,285 196,971 1,053,805 984,794Net income$698,681 $502,393 $2,624,730 $2,553,955 Basic earnings per share$0.31 $0.23 $1.18 $1.14Diluted earnings per share$0.31 $0.23 $1.18 $1.14 For the three months ended For the nine months ended December 31 December 31 2020 2019 2020 2019 KEY FINANCIAL RATIOS (unaudited) Annualized return on average equity 11.37% 8.31% 10.69% 11.03%Annualized return on average assets 0.89% 0.85% 0.92% 1.17%Net interest margin 3.66% 4.41% 3.81% 4.46%Core efficiency ratio 56.04% 71.16% 59.74% 64.50%Net chargeoffs/(recoveries) to average loans 0.008% 0.002% -0.07% -0.05% AVERAGE BALANCES (thousands, unaudited) Average assets $313,827 $235,723 $284,525 $219,167 Average interest-earning assets $292,210 $177,259 $246,617 $183,108 Average gross loans $192,418 $136,963 $173,927 $136,504 Average deposits $253,908 $186,587 $224,971 $179,226 Average equity $24,583 $24,182 $24,551 $23,156 CREDIT QUALITY End of period (unaudited) December 31, 2020 December 31, 2019 Non-performing loans $119,836 $120,423 Non-performing loans to total loans 0.06% 0.08% Non-performing loans to total assets 0.04% 0.05% Allowance for loan losses to total loans 1.67% 1.66% Nonperforming assets as a percentage of total loans and OREO 0.06% 0.08% Allowance for loan losses to non-performing loans 2730.33% 1986.14% OTHER PERIOD-END STATISTICS (unaudited) Shareholders equity to total assets 8.65% 10.62% Net loans to deposits 74.00% 78.58% Non-interest bearing deposits to total deposits 56.43% 49.08% Community Bank Leverage Ratio 11.44% 13.74%

  • Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Splunk Inc. (SPLK)

    LOS ANGELES, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Splunk Inc. (“Splunk” or the “Company”) (NASDAQ: SPLK) common stock between August 26, 2020 and December 2, 2020, inclusive (the “Class Period”). If you suffered a loss on your Splunk investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/splunk-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On December 2, 2020, after the market closed, Splunk announced its third quarter 2021 financial results in a press release. Therein, the Company reported total revenue of $559 million, down 11% year-over-year. The Company also announced quarterly non-GAAP earnings per share of -$0.07, missing estimates by 15 cents. Analysts at JP Morgan were allegedly “blindsided by the magnitude of too many large deals slipping in the final days of October.” On this news, the Company’s stock price fell by $47.88 per share, or approximately 23%, to close at $158.03 per share on December 3, 2020. The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired Splunk common stock during the Class Period, you may move the Court no later than February 2, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay & Murray LLP, Los Angeles Charles Linehan, 310-201-9150 or 888-773-9224 shareholders@glancylaw.com www.glancylaw.com

  • Server Software Market Research Report - Global Forecast to 2024 - Cumulative Impact for COVID-19 Recovery | SpendEdge

    The Server Software market will register an incremental spend of about USD 46.92 billion, growing at a CAGR of 22.08% from 2020-2024

  • FBIO Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fortress Biotech, Inc. Investors of Class Action and Lead Plaintiff Deadline: January 26, 2021

    Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fortress Biotech, Inc. ("Fortress Biotech" or "the Company") (NASDAQ: FBIO) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fortress Biotech securities between December 11, 2019 and October 9, 2020 both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fbio.

  • Orion Pledges 2021 War Chest of New Resources, Events for Breakaway Advisors

    Orion Advisor Solutions, the premier provider of the tech-enabled fiduciary framework that empowers financial advisors to Prospect, Plan, Invest, and Achieve within a single, connected experience, will make 2021 the year of the breakaway advisor. Orion is investing in bold initiatives — including collaborative virtual and in-person events, a growing digital trove of practical guides, a network of Orion client firms for advisors to "tuck into" while still retaining their independence, and special pricing deals — all to support the growing number of advisors who dream of establishing and growing independent firms.

  • Electric Bed Market Value Anticipated To Reach Around US$ 4,010.4 Mn By 2027: Acumen Research and Consulting

    Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Electric Bed Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”LOS ANGELES, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Global Electric Bed Market is expected to grow at a CAGR of around 6.9% from 2020 to 2027 and reach the market value of over US$ 4,010.4 Mn by 2027. Download Sample Pages of this report@ https://www.acumenresearchandconsulting.com/request-sample/2395 Electric beds are particularly designed for those who have mobility issues and are living alone. These beds help in controlling sleeping positions by allowing adjustment of both upper and lower body positions and the height of the bed itself. The increasing number of patients with mobility issues along with the rapidly increasing geriatric population is further bolstering the market value. The increasing number of patients with chronic diseases are likely to need hospitalization at some point in time, which is further expected to create demand over the forecast period from 2020 to 2027. According to International Diabetes Federation (IDF), 11.3% of the total population in Southeast Asia, i.e. 87.6 million people, was diagnosed with diabetes in 2019 and the number is projected to reach 12.6% by 2045. The electric bed market is segmented on the basis of product, application, end-use, and geography. Based on product, the market is divided into semi-automatic electric beds and fully automatic electric beds. Electric beds have applications across the general beds, intensive care beds, bariatric beds, birthing beds, and others. Additionally, the end-use segments include hospitals & clinics, reproductive care centers, dentistry, and others. View Table of Content of this report@ https://www.acumenresearchandconsulting.com/electric-bed-market By product, the semi-automatic electric bed segment is leading with the electric bed market with a major revenue share and the segment is also projected to maintain its dominance over the forecast period from 2020 to 2027. The high adoption of semi-automatic electric beds in the healthcare sector is supporting the growth due to their cost efficiency and early invention. Based on the application, the general bed segment accounted for the maximum revenue share in the global market. The increasing installation of electric beds in hospitals in order to provide better patient care to the increasing number of patients in the hospital is supporting the segmental market value. In 2019, North America held the major share (%) of the global electric bed market, and the region is also projected to maintain its dominance over the forecast period from 2020 to 2027. The presence of major players in the region including Gendron Inc. (US), Stryker (US), Medline Industries, Inc. (US), Hill-Rom Services Inc. (Chicago), and Invacare Corporation (US) among others are supporting the regional market value. Asia Pacific is likely to exhibit the fastest growth with a major CAGR (%) over the estimated period from 2020 to 2027. The emerging economies of the region including China, India are majorly contributing to the regional market value. The rapidly developing healthcare infrastructure of the region along with the major investment by the public as well as private authorities is bolstering the demand for electric beds in the regional market. Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Some of the leading competitors are Getinge Group (Arjo), Gendron Inc., Hill-Rom Services Inc., Invacare Corporation, LINET, Malvestio Spa, Medline Industries, Inc., Midmark India Pvt. Ltd., Paramount Bed Co., Ltd., and Stryker. Electric Bed companies have announced mergers and acquisitions, partnerships & collaboration, and new product development to uplift their position in the electric bed industry. Major players are also moving into new regions with advanced technologies for gaining a competitive advantage in the regional market. Some of the key observations regarding the electric bed industry include: Xiaomi has launched the 8H Milan Smart Electric Bed Pro under the Youpin crowdfunding platform in October 2020. The new launch is the direct successor to the 8H Milan smart electric bed which was launched under crowdfunding in December 2019. The 8H Milan Smart Electric Bed Pro is priced at 4899 yuan ($735).Stryker Corporation, an American multinational medical technologies corporation has announced a completely new wireless hospital bed that sports a number of smart patient monitoring features. The ProCuity, series of beds include Stryker’s Secure Connect technology that provides a wireless way to connect to nurse call systems. The ProCuity bed series even include electric brakes that help to maintain safety.Electric bed retailer Revitalife using 'sleep survey' as a sales tool and the company is claiming that its expensive adjustable beds help older Australians sleep better. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2395 Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/2395 Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting/

  • Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)

    LOS ANGELES, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between April 24, 2019 and November 16, 2020, inclusive (the “Class Period”). If you suffered a loss on your Boston Scientific investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/boston-scientific-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On November 17, 2020, Boston Scientific announced a worldwide recall of all unused inventory of the LOTUS Edge Aortic Valve System, a transcatheter aortic valve replacement product which had been approved by the U.S. Food and Drug Administration (“FDA”) in April 2019. Citing "complexities associated with the product delivery system" and the “additional time and investment required to develop and reintroduce an enhanced delivery system,” the Company stated that it had "chosen to retire the entire LOTUS product platform immediately." On this news, Boston Scientific's stock price fell $3.00 per share, or approximately 8%, to close at $35.03 per share on November 17, 2020, thereby injuring investors. The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (2) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired Boston Scientific securities during the Class Period, you may move the Court no later than February 2, 2021 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay & Murray LLP, Los Angeles Charles Linehan, 310-201-9150 or 888-773-9224 shareholders@glancylaw.com www.glancylaw.com